Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Drug

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Fineline Cube May 6, 2026
Company

FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results

Fineline Cube Nov 7, 2023

US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...

Company Deals

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

Fineline Cube Nov 7, 2023

GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...

Company Drug

Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy

Fineline Cube Nov 7, 2023

Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...

Company Drug

Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil

Fineline Cube Nov 7, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...

Company Deals

WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares

Fineline Cube Nov 7, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial

Fineline Cube Nov 7, 2023

Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...

Company Deals Hospital Medical Device

Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery

Fineline Cube Nov 7, 2023

China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic...

Company

Danone Enters China’s Adult FSMP Market with Local Production of Fortimel

Fineline Cube Nov 7, 2023

France-based food company Danone has revealed its strategic plans to enter the adult foods for...

Company Deals

SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China

Fineline Cube Nov 7, 2023

China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...

Company Drug

RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002

Fineline Cube Nov 7, 2023

RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...

Company Drug

Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China

Fineline Cube Nov 7, 2023

The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...

Company Deals

Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA

Fineline Cube Nov 7, 2023

Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with...

Company Deals

Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China

Fineline Cube Nov 7, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a...

Company Medical Device

Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE

Fineline Cube Nov 7, 2023

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group)...

Company Deals

BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal

Fineline Cube Nov 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...

Company Drug

MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries

Fineline Cube Nov 6, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...

Company Deals

Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China

Fineline Cube Nov 6, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Company Deals

CORXEL Partners with WuXi STA for Sterile Nasal Spray Production

Fineline Cube Nov 6, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...

Company Drug

Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management

Fineline Cube Nov 6, 2023

Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...

Company Drug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Fineline Cube Nov 6, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Posts pagination

1 … 442 443 444 … 660

Recent updates

  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
  • China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Company

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.